In 2009, no medtech firm was more active in the M&A market than Covidien. Along with a relocation to Ireland and having to face the challenges of an ongoing imaging isotope shortage, it has been a busy year for the firm. Joseph Harvey spoke with chairman, president and CEO Richard ...
Please Login to read the full article.
